0000000000902755

AUTHOR

Murat Akova

showing 4 related works from this author

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic an…

2016

Objectives: We utilized the database of the Defining Antibiotic Levels in Intensive care unit patients (DALI) study to statistically compare the pharmacokinetic/pharmacodynamic and clinical outcomes between prolonged- infusion and intermittent-bolus dosing of piperacillin/tazobactam and meropenem in critically ill patients using inclusion criteria similar to those used in previous prospective studies. Methods: This was a post hoc analysis of a prospective, multicentre pharmacokinetic point-prevalence study (DALI), which recruited a large cohort of critically ill patients from 68 ICUs across 10 countries. Results: Of the 211 patients receiving piperacillin/tazobactam and meropenem in the DAL…

0301 basic medicineMalePenicillanic Acidintensive care unitlaw.inventionthienamycin derivative abdominal infection[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawcentral nervous system infectioncreatinine clearancePharmacology (medical)Infusions IntravenouProspective StudiesInfusions IntravenousProspective cohort studyTazobactam Drug CombinationAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Meropenem; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Microbiology (medical); Pharmacology (medical); Infectious Diseasescritical illneMicrobial Sensitivity TestadultRespiratory infectionclinical trialMiddle Agedcontinuous infusionanalogs and derivativeIntensive care unit3. Good healthAnti-Bacterial Agentsantiinfective agentintravenous drug administrationIntensive Care Units[SDV.MP]Life Sciences [q-bio]/Microbiology and ParasitologyTreatment OutcomeInfectious DiseasesPiperacillin/tazobactammulticenter study (topic)SOFA scoreFemaletreatment outcome AgedIntravenousprospective studyHumanmedicine.drugsurvival rateMicrobiology (medical)medicine.medical_specialtyInfusionspost hoc analysirespiratory tract infectionCritical IllnessAged; Anti-Bacterial Agents; Blood Chemical Analysis; Critical Illness; Female; Humans; Infusions Intravenous; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Prospective Studies; Thienamycins; Treatment Outcome; Pharmacology; Pharmacology (medical); Infectious Diseases030106 microbiologybloodstream infectionMicrobial Sensitivity Testsminimum inhibitory concentrationpiperacillin plus tazobactamMeropenemTazobactamArticle03 medical and health sciencescritically ill patientInternal medicineAnti-Bacterial AgentmedicineSequential Organ Failure Assessment ScoreHumansThienamycinsurvival timeblood analysiAgedPiperacillinPharmacologybusiness.industryBlood Chemical AnalysiMeropenemmajor clinical studySurgeryProspective Studiemulticenter studyPharmacology; Pharmacology (medical); Infectious Diseases[SDV.SP.PHARMA]Life Sciences [q-bio]/Pharmaceutical sciences/PharmacologyThienamycinspiperacillin tazobactam drug combinationurinary tract infectionbusinessBlood Chemical AnalysisPiperacillin
researchProduct

European expert opinion on the management of invasive candidiasis in adults

2011

Item does not contain fulltext This report discusses the present status of antifungal therapy and treatment options for candidaemia, considered by experts in the field in Europe. A conference of 26 experts from 13 European countries was held to discuss strategies for the treatment and prevention of invasive candidiasis, with the aim of providing a review on optimal management strategies. Published and unpublished comparative trials on antifungal therapy were analysed and discussed. Commonly asked questions about the management of candidaemia were selected, and possible responses to these questions were discussed. Panellists were then asked to respond to each question by using a touchpad ans…

Invasive mycoses and compromised host Translational research [N4i 2]AdultMicrobiology (medical)medicine.medical_specialtyAntifungal Agentsmedicine.medical_treatmentPlacebo-controlled studyMEDLINEInvasive mycoses and compromised host Infection and autoimmunity [N4i 2]MicrobiologyMedicineHumanscandidaemiaCandidiasis InvasiveguidelinesIntensive care medicineWatchful Waitingtherapybusiness.industryTreatment optionsPathogenesis and modulation of inflammation Infection and autoimmunity [N4i 1]General MedicineInvasive candidiasisComparative trialAntibiotic Prophylaxismedicine.diseaseOptimal managementEuropeIntensive Care UnitsInfectious DiseasesconsensusExpert opinioncandidabusinessWatchful waitingClinical Microbiology and Infection
researchProduct

Epidemiology and outcomes of hospital-acquired bloodstream infections in intensive care unit patients: the EUROBACT-2 international cohort study.

2023

Purpose: In the critically ill, hospital-acquired bloodstream infections (HA-BSI) are associated with significant mortality. Granular data are required for optimizing management, and developing guidelines and clinical trials. Methods: We carried out a prospective international cohort study of adult patients (≥ 18 years of age) with HA-BSI treated in intensive care units (ICUs) between June 2019 and February 2021. Results: 2600 patients from 333 ICUs in 52 countries were included. 78% HA-BSI were ICU-acquired. Median Sequential Organ Failure Assessment (SOFA) score was 8 [IQR 5; 11] at HA-BSI diagnosis. Most frequent sources of infection included pneumonia (26.7%) and intravascular catheters…

antibiotic resistancebloodstream infectionhospital-acquiredbacteremiaCritical Care and Intensive Care Medicineantibiotic resistance ; bacteremia ; bloodstream infection ; hospital-acquired.
researchProduct

Antimicrobial de-escalation in the critically ill patient and assessment of clinical cure : the DIANA study

2020

© 2020 The Author(s).

OriginalDELPHI METHODCritical Care and Intensive Care MedicineGUIDELINESlaw.invention0302 clinical medicineAnti-Infective Agents[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseaseslawEpidemiologyMedicine and Health SciencesAntimicrobial de-escalationEPIDEMIOLOGYComputingMilieux_MISCELLANEOUS[SDV.MHEP.ME]Life Sciences [q-bio]/Human health and pathology/Emerging diseasesVentilator-associated pneumoniaIntensive care unitAnti-Bacterial Agents3. Good healthIntensive Care UnitsSTEWARDSHIP PROGRAM[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/VirologyCohortAntimicrobial de-escalation; Bacterial infection; Clinical cure; Empirical therapy; Intensive care unit;Clinical cureAntimicrobial de-escalation; Bacterial infection; Clinical cure; Empirical therapy; Intensive care unitAdultmedicine.medical_specialtyCombination therapyCritical IllnessANTIBIOTIC-THERAPYNO03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemBETA-LACTAMInternal medicineSettore MED/41 - ANESTESIOLOGIAmedicineHumans[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyIntensive care unitVENTILATOR-ASSOCIATED PNEUMONIAbusiness.industrySEPTIC SHOCKR-PACKAGEbacterial infectionIntensive care unit.030208 emergency & critical care medicinemedicine.disease[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/BacteriologyEmpirical therapyDiscontinuationSEVERE SEPSISlnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4]Carbapenems030228 respiratory systemRelative riskBacterial infectionbusinessDe-escalation
researchProduct